API | mocetinostat

mocetinostat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia. ^Wikipedia

Chemistry

SMILES: Nc1ccccc1NC(=O)c2ccc(CNc3nccc(n3)c4cccnc4)cc2
InChIKey: HRNLUBSXIHFDHP-UHFFFAOYSA-N
Mol. Mass: 396.45
ALogP: 3.99 Partition coefficient
ChEMBL Molecule:
mocetinostat

More Chemistry

Pharmacology

Mechanisms of Action:
- Histone deacetylase 1 (Homo sapiens) ^UniProt
- Histone deacetylase 11 (Homo sapiens) ^UniProt
- Histone deacetylase 2 (Homo sapiens) ^UniProt
- Histone deacetylase 3 (Homo sapiens) ^UniProt
- Histone deacetylase 8 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

mg0103 | mg 0103 | mg-0103 | mg4230 | mg 4230 | mg-4230 | mg4915 | mg 4915 | mg-4915 | mg 5026 | mg-5026 | mg5206 | mgcd0103 | mgcd 0103 | mgcd-0103 | mocetinostat | n-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide

Organizations (14)

Research & Development (14)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (20)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (20)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Hodgkin Disease (Phase 2)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 1)

Rhabdomyosarcoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 23
# of Trial Organizations: 14

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue